Review: Biochemical mechanisms of antibiotic resistance

Introduction

What happens when bacteria evolve faster than our ability to develop new antibiotics? This sobering question defines the antimicrobial resistance crisis threatening global health security [1] . Since Alexander Fleming first observed bacterial resistance shortly after discovering penicillin, microorganisms have demonstrated remarkable capacity to neutralize every antibiotic introduced into clinical practice [2] . The biochemical mechanisms underlying this adaptive success reveal sophisticated strategies for survival that bacteria have refined over millions of years of evolutionary competition [3] . Antimicrobial resistance mechanisms can be broadly categorized into four principal biochemical strategies: enzymatic inactivation of the antibiotic molecule, modification of the drug target site, active efflux from the bacterial cell, and reduced permeability limiting drug entry [4] . Individual bacteria may employ multiple mechanisms simultaneously, creating formidable barriers to treatment. Mobile genetic elements facilitate rapid dissemination of resistance determinants within and between bacterial species, accelerating the spread of resistance across clinical settings and geographic boundaries [5] . The clinical consequences of antimicrobial resistance extend beyond individual treatment failures to threaten the foundations of modern medicine. Surgical procedures, cancer chemotherapy, and organ transplantation depend upon effective antibiotic prophylaxis and treatment of inevitable infections [6] . Without functional antibiotics, mortality from common infections could return to pre-antibiotic era levels, reversing nearly a century of medical progress [7] . Understanding resistance biochemistry at the molecular level provides essential foundation for developing countermeasures including novel antibiotic scaffolds designed to evade existing resistance mechanisms, adjuvant compounds that inhibit resistance enzymes, and diagnostic tools enabling rapid identification of resistance profiles to guide therapy [8] . This review synthesizes current knowledge of antibiotic resistance mechanisms across major drug classes, examines the genetic basis of resistance acquisition and dissemination, and discusses implications for therapeutic development and clinical practice [9] .

Material and Methods

Search strategy

This narrative review was conducted following established guidelines for comprehensive literature synthesis. Systematic searches of PubMed, Web of Science, and Scopus databases were performed using combinations of keywords including antibiotic resistance, resistance mechanisms, beta-lactamase, efflux pump, target modification, and enzymatic inactivation. Searches were limited to English language publications from January 2000 through December 2023 to capture both foundational mechanistic research and recent developments [10] .

Reference lists of identified articles and relevant reviews were screened for additional sources. Priority was given to peer-reviewed original research articles, authoritative reviews from leading journals, and consensus documents from international expert bodies. Grey literature including conference proceedings and surveillance reports from the World Health Organization and European Centre for Disease Prevention and Control supplemented peerreviewed sources for epidemiological data [11] .

Selection criteria

Articles were included if they provided mechanistic characterization of resistance pathways, epidemiological data on resistance prevalence, clinical outcome data related to resistant infections, or discussed therapeutic strategies addressing resistance. Exclusion criteria included case reports without mechanistic analysis, articles focusing exclusively on agricultural or environmental settings without clinical relevance, and studies with significant methodological limitations as assessed by the authors [12] .

Results

Enzymatic inactivation mechanisms

Enzymatic destruction or modification of antibiotic molecules before they reach their cellular targets represents the most prevalent resistance mechanism for several major drug classes. Beta-lactamases hydrolyze the essential fourmembered ring structure of penicillins, cephalosporins, and carbapenems, rendering these antibiotics incapable of inhibiting cell wall synthesis enzymes [13] . The Ambler classification system organizes beta-lactamases into four molecular classes based on amino acid sequence homology: Class A serine beta-lactamases including TEM, SHV, and CTX-M families; Class B metallo-beta-lactamases requiring zinc cofactors; Class C AmpC cephalosporinases; and Class D OXA-type enzymes [14] . Extended-spectrum beta-lactamases have emerged as particularly concerning resistance determinants, conferring resistance to third-generation cephalosporins that were once considered reliable treatments for serious Gram-negative infections. CTX-M enzymes have achieved global dominance among ESBLs, with CTX-M-15 representing the most widely disseminated variant [15] . Carbapenemases capable of hydrolyzing last-resort carbapenem antibiotics pose even greater therapeutic challenges, with KPC, NDM, and OXA-48-like enzymes spreading rapidly across clinical settings worldwide [16] .

Target modification mechanisms

Alteration of antibiotic target sites through mutation or enzymatic modification reduces drug binding affinity while maintaining essential cellular functions. Fluoroquinolone resistance commonly arises through mutations in DNA gyrase and topoisomerase IV genes, with stepwise accumulation of mutations in quinolone resistancedetermining regions producing increasing resistance levels [17] . Single mutations typically confer low-level resistance, while high-level resistance requires multiple mutations in both target enzymes. Ribosomal target modifications mediate resistance to macrolides, lincosamides, and streptogramins through erm genes encoding methylases that add methyl groups to 23S ribosomal RNA. This modification prevents antibiotic binding while permitting normal ribosome function [18] . Glycopeptide resistance in enterococci results from acquisition of van gene clusters that reprogram cell wall precursor synthesis, replacing the D-alanyl-D-alanine terminus with D-alanyl-D-lactate, reducing vancomycin binding affinity by approximately one thousand-fold [19] .

Efflux pump systems

Active efflux represents a ubiquitous resistance mechanism capable of expelling structurally diverse antibiotics from bacterial cells. Five major efflux pump superfamilies have been characterized: the resistance-nodulation-division family, major facilitator superfamily, multidrug and toxic compound extrusion family, ATP-binding cassette superfamily, and small multidrug resistance family [20] . The RND family AcrAB-TolC system in Enterobacteriaceae exemplifies tripartite efflux pumps spanning the inner membrane, periplasm, and outer membrane to export substrates directly to the external environment. Efflux pump overexpression, often resulting from regulatory mutations, can confer clinically significant resistance to fluoroquinolones, tetracyclines, macrolides, and betalactams simultaneously [21] . The broad substrate specificity of many efflux systems contributes substantially to multidrug resistance phenotypes, and efflux frequently synergizes with other resistance mechanisms to produce high-level resistance.

Global epidemiology of resistance

The global distribution of antibiotic resistance demonstrates significant geographic variation, with highest prevalence generally observed in South and Southeast Asia, followed by the Middle East and parts of Africa [22] . ESBL-producing Enterobacteriaceae have achieved pandemic distribution, with community-acquired infections now common in regions where these organisms were previously confined to healthcare settings. Carbapenemase-producing organisms show more heterogeneous distribution patterns, with endemic regions including the Indian subcontinent for NDM, the Mediterranean basin for OXA-48-like enzymes, and China for KPC [23] .

Discussion

This review highlights the biochemical complexity underlying antimicrobial resistance and the sophisticated strategies bacteria employ to survive antibiotic exposure. Enzymatic inactivation, target modification, efflux pumps, and permeability barriers represent distinct but often synergistic resistance mechanisms that collectively pose formidable therapeutic challenges. Understanding these mechanisms at the molecular level is essential for developing effective countermeasures.

The dominance of enzymatic inactivation in beta-lactam and aminoglycoside resistance has driven development of inhibitor combinations including novel beta-lactamase inhibitors such as avibactam and vaborbactam that extend coverage to some carbapenemase-producing organisms [24] . However, metallo-beta-lactamases remain largely unaddressed by currently available inhibitors, representing a critical unmet need. The broad substrate specificity of efflux pumps makes them attractive targets for adjuvant therapy, though clinical development of efflux pump inhibitors has proven challenging [25] . Mobile genetic elements including plasmids, transposons, and integrons facilitate rapid dissemination of resistance genes within and between bacterial species, accelerating resistance spread far beyond rates achievable through chromosomal mutation alone. The association of resistance determinants with mobile elements of broad host range enables rapid geographic dissemination and accumulation of multiple resistance mechanisms in single organisms, generating extensively drug-resistant and pan-drug-resistant phenotypes of great clinical concern [26] . Future directions for addressing antimicrobial resistance must include not only development of novel antibiotics with activity against resistant organisms but also strategies to slow resistance emergence and dissemination. Antimicrobial stewardship programs optimizing antibiotic use, infection prevention measures reducing transmission of resistant organisms, rapid diagnostic tools guiding appropriate therapy, and alternative approaches including bacteriophages, antimicrobial peptides, and immunomodulatory therapies all contribute to comprehensive resistance mitigation strategies [27] .

Conclusion

Antimicrobial resistance represents a multifaceted biochemical challenge requiring comprehensive understanding of resistance mechanisms for effective therapeutic response. Enzymatic inactivation through betalactamases and aminoglycoside-modifying enzymes remains the predominant mechanism for these critical drug classes, while target modification, efflux pumps, and permeability barriers contribute variably across antibiotic families. The interplay of multiple resistance mechanisms frequently produces high-level, multidrug-resistant phenotypes that severely limit treatment options. Global surveillance data reveal alarming prevalence of resistance genes, particularly ESBL and carbapenemase determinants, with highest rates in Asia and the Middle East. The emergence of transferable colistin resistance mediated by MCR genes threatens effectiveness of this lastresort antibiotic against carbapenem-resistant organisms. Geographic variation in resistance patterns necessitates region-specific surveillance and treatment guidelines. Addressing the resistance crisis requires sustained investment in novel antibiotic development, particularly agents active against Gram-negative pathogens and metallobeta-lactamase producers. Adjuvant therapies targeting resistance mechanisms offer promise for extending the utility of existing antibiotics. Implementation of antimicrobial stewardship, infection prevention, and rapid diagnostics are essential components of comprehensive resistance mitigation. The biochemical sophistication of bacterial resistance mechanisms reflects millions of years of evolutionary refinement. Understanding these mechanisms provides the foundation for developing countermeasures capable of preserving antibiotic effectiveness for future generations. Continued research into resistance biochemistry remains essential for maintaining our therapeutic armamentarium against infectious diseases.

Acknowledgement

Acknowledgements Funding sourcesThis review was supported by the Chaopraya Institute of Medical Sciences research fund and the Thailand Research Fund antimicrobial resistance program. Institutional supportThe authors acknowledge the Chaopraya Institute library services for assistance with literature searches and the Department of Microbiology for providing access to relevant databases and resources.

References

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655.
2. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews. 2010;74(3):417-433.
3. D'Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature. 2011;477(7365):457-461.
4. Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology. 2015;13(1):42-51.
5. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clinical Microbiology Reviews. 2018;31(4):e00088-17.
6. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance the need for global solutions. Lancet Infectious Diseases. 2013;13(12):1057-1098.
7. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance. London; 2016.
8. Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends in Microbiology. 2016;24(11):862-871.
9. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiology Spectrum. 2016;4(2):VMBF0016-2015.
10. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Information and Libraries Journal. 2009;26(2):91-108.
11. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. Geneva: WHO; 2022.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Medicine. 2009;6(7):e1000097.
13. Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harbor Perspectives in Medicine. 2016;6(8):a025247.
14. Ambler RP. The structure of β-lactamases. Philosophical Transactions of the Royal Society B. 1980;289(1036):321-331.
15. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. Journal of Antimicrobial Chemotherapy. 2017;72(8):2145-2155.
16. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. Journal of Infectious Diseases. 2017;215(suppl_1):S28-S36.
17. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Annals of the New York Academy of Sciences. 2015;1354(1):12-31.
18. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: Nature of the resistance elements and International Journal of Advanced Biochemistry Research https://www.biochemjournal.com their clinical implications. Clinical Infectious Diseases. 2002;34(4):482-492.
19. Courvalin P. Vancomycin resistance in gram-positive cocci. Clinical Infectious Diseases. 2006;42(Suppl 1):S25-S34.
20. Li XZ, Plésiat P, Nikaido H. The challenge of effluxmediated antibiotic resistance in Gram-negative bacteria. Clinical Microbiology Reviews. 2015;28(2):337-418.
21. Poole K. Efflux-mediated antimicrobial resistance. Journal of Antimicrobial Chemotherapy. 2005;56(1):20-51.
22. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum βlactamases in the community: toward the globalization of CTX-M. Clinical Microbiology Reviews. 2013;26(4):744-758.
23. Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors in the clinic. Infectious Disease Clinics of North America. 2016;30(2):441-464.
24. Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gramnegative bacteria. PLoS One. 2013;8(3):e60666.
25. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281.
26. Theuretzbacher U, Outterson K, Engel A, Karlén A. The global preclinical antibacterial pipeline. Nature Reviews Microbiology. 2020;18(5):275-285.